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Abstract
Estrogen signaling is a critical pathway that plays a key role in the pathogenesis of breast cancer.
In a previous transcriptional profiling study, we identified a novel panel of estrogen-induced genes
in breast cancer. One of these genes is solute carrier family 22 member 5 (SLC22A5), which
encodes a polyspecific organic cation transporter (also called OCTN2). In this study, we found
that estrogen stimulates SLC22A5 expression robustly in an estrogen receptor (ER)-dependent
manner and that SLC22A5 expression is associated with ER status in breast cancer cell lines and
tissue specimens. Although the SLC22A5 proximal promoter is not responsive to estrogen, a
downstream intronic enhancer confers estrogen inducibility. This intronic enhancer contains a
newly identified estrogen-responsive element (ERE) (GGTCA-CTG-TGACT) and other
transcription factor binding sites, such as a half ERE and a nuclear receptor related 1 (NR4A2/
Nurr1) site. Estrogen induction of the luciferase reporter was dependent upon both the ERE and
the NR4A2 site within the intronic enhancer. Small interfering RNA against either ER or Nurr1
inhibited estrogen induction of SLC22A5 expression, and chromatin immunoprecipitation assays
confirmed the recruitment of both ER and Nurr1 to this enhancer. In functional assays,
knockdown of SLC22A5 inhibited L-carnitine intake, resulted in lipid droplet accumulation, and
suppressed the proliferation of breast cancer cells. These results demonstrate that SLC22A5 is an
estrogen-dependent gene regulated via a newly identified intronic ERE. Since SLC22A5 is a
critical regulator of carnitine homeostasis, lipid metabolism, and cell proliferation, SLC22A5 may
serve as a potential therapeutic target for breast cancer in the future.
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Introduction
Breast cancer is the most frequently diagnosed cancer and the second leading cause of
cancer-related deaths in women [1]. Among many factors that contribute to the development
and progression of breast cancer, estrogen signaling is regarded as the most critical one,
playing a key role in the development, progression, prevention, and treatment of the disease
[2, 3]. The effects of estrogen on breast cancer are primarily mediated by estrogen receptor
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alpha (ER), a member of the nuclear receptor superfamily [3–5]. Previous studies have
demonstrated that estrogen and ER regulate target gene expression via several different
mechanisms [6–9], including the classical genomic pathway [10], transcription factor
crosstalk, also known as the tethering pathway [11, 12], and the non-genomic (cytoplasmic)
pathway [13–15]. Recently, genome-wide ER binding sites have been identified [16, 17].
These studies demonstrate that many estrogen-regulated genes do not have consensus
estrogen-response elements (EREs) in their promoters. In addition, this data identifies the
positioning of ER binding sites in distal regions not previously annotated as cis-regulatory
elements rather than in the proximal promoter regions.
To further investigate the molecular mechanism of estrogenic effects on breast cancer, we
have performed transcriptional profiling experiments and identified a novel panel of
estrogen-induced genes in breast cancer [18]. Many identified genes are critical regulators of
cell cycle, cell growth, and metabolism. While the effects of estrogen on breast cancer cell
cycle and growth have been well documented in our previous studies [11, 12], estrogenic
effects on metabolism remain understudied. Among the estrogen-induced genes we
identified, solute carrier family 22 member 5 (SLC22A5) is of particular interest as it
encodes a polyspecific organic cation transporter (OCTN2) that carries a high affinity for
carnitine [19, 20]. Carnitine has been implicated in lipid metabolism, because it is essential
for the transfer of fatty acids across the inner mitochondrial membrane before β-oxidation
[21–23], and OCTN2 is primarily responsible for carnitine-reabsorption in the kidney once it
has been filtered. Mutations in SLC22A5 gene and polymorphisms in its promoter have
been associated with many diseases, including type 1 diabetes (T1D) [24], chronic
inflammatory disease of the gastrointestinal tract (Crohn’s disease) [25], and systemic
primary carnitine deficiency (hypoketotic hypoglycemia and skeletal/cardio-myopathy) [26–
29]. However, little information is available regarding the role of the SLC22A5 gene in
cancer.
In this study, we show that SLC22A5 is an ER-dependent gene and that its expression is
associated with ER status in both breast cancer cells and tumor specimens. We also define
the molecular mechanism by which estrogen regulates SLC22A5 expression in breast cancer
cells. Specifically, the SLC22A5 proximal promoter is not sensitive to estrogen. However,
within the +9 kb region downstream of the transcriptional start site of the SLC22A5 gene is
an estrogen-activated intronic enhancer element containing a novel ERE. Furthermore, we
found that SLC22A5 is critical for carnitine intake, lipid metabolism, and cell proliferation.
This study therefore identifies SLC22A5 as a newly discovered intronic ERE-dependent




The breast cancer cell lines BT474, BT483, HCC1428, HCC1500, HS578T, MCF-7, MDA-
MB-231, MDA-MB-361, MDA-MB-415, MDA-MB-453, MDA-MB-468, SKBr3,
SUM-159PT, T47D, and ZR75-1 were purchased from American Type Culture Collection
(ATCC, Manassas, VA).
Chemicals and treatment
17-β-estradiol (E2), 12-O-tetradecanoyl-phorbol-13-acetate (TPA), forskolin (FSK), ICI
182.780 (ICI), actinomycin D (ActD), and cycloheximide (CHX) were purchased from
Sigma-Aldrich (St. Louis, MO) and dissolved in ethanol or dimethyl sulfoxide (DMSO).
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The final concentrations of E2, TPA, FSK, ICI, ActD, and CHX were 1 nmol/l, 100 nmol/l,
10 μmol/l, 1 μmol/l, 1 μg/ml, and 10 μg/ml, respectively.
Constructs
The CMV-Nurr1 plasmid was purchased from OriGene (Rockville, MD). The −5.7 kb L and
−5.0 kb LΔE SLC22A5 promoter plasmids were generously provided by Dr. Bing Ren [30].
The SLC22A5 proximal promoter region (−527 to +39 bp) was amplified by PCR and
inserted into the pGL3basic plasmid. The +9 kb downstream enhancer region (1,063 bp) was
cloned by PCR from human genomic DNA. Primer sequences are listed in Supplemental
Table 1. For site-directed mutagenesis, the half ERE (hERE) GGTCA was mutated to
GagCA and the hERE TGACC/T was mutated to TGctC/T; the cyclic adenosine
monophosphate (cAMP)-response element (CRE) TGACATCA was mutated to TtctATCA;
the nuclear receptor subfamily 4, group A, member 2 (NR4A2) site AtGTCA was mutated
to AtagaA. All constructs were verified by sequencing.
Luciferase assay
Hormone-depleted MCF-7 cells were transfected with plasmids using FuGENE 6
Transfection Reagent (Roche, Basel, Switzerland). The next day, cells were treated with E2
for 6 h. Luciferase activity was measured using a commercially available kit (Promega,
Madison, WI).
RNA extraction and quantitative RT-PCR (qRT-PCR)
Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen, Valencia, CA), then
reverse transcribed. qRT-PCR was carried out on an ABI 7900HT Fast Real-Time PCR
System (Applied Biosystems/Life Technologies, Carlsbad, CA). The relative gene
expression was determined using the comparative CT method as previously described [31].
Primers and probes are listed in Supplemental Table 1.
Small interfering RNA (siRNA) experiment
Cells were transfected with chemically synthesized siRNAs (Sigma, St. Louis, MO) using
RNAiMAX Transfection Reagent (Invitrogen, Carlsbad, CA). siRNA for the luciferase gene
(Sigma) was used as a control.
Western blot
Total protein was extracted from cells using RIPA buffer containing protease inhibitors
(Roche). 30 μg protein per lane was resolved by SDS-PAGE and transferred to a
nitrocellulose membrane. After incubating sequentially with primary and secondary
antibodies, blots were developed using the SuperSignal West Pico Kit (Pierce, Rockford, IL)
and exposed to film.
Chromatin immunoprecipitation (ChIP)
ChIP experiments were performed according to the published protocols with minor
modifications [11, 12, 18, 32]. Primers and probes are listed in Supplemental Table 1. The
recruitment was presented as the ratio of the q-PCR result of immunoprecipitated fragments
normalized to the total input DNA.
Breast cancer tissue datasets
Clinical microarray datasets consisting of primary breast cancer tissue specimens were used
to analyze the association between ER and SLC22A5 expression in breast cancer specimens
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[33–47]. ER and SLC22A5 probe set IDs, corresponding annotations, and clinical data were
extracted from these datasets.
Carnitine transport assay
Prior to carnitine transport assays, cells were washed three times with PBS. Carnitine
hydrochloride, L-[N-methyl-3H] (100 μmol/l final concentration, 89.5 Ci/mmol,
PerkinElmer, Waltham, MA) were added to the cells. At the indicated times, cells were
washed three times with cold PBS and harvested. Radioactivity was quantified using a liquid
scintillation counter (Beckman Coulter LS-6500).
Lipid droplets assay
Cells were seeded in 96-well plates, transfected with SLC22A5 siRNA for 2 days, and then
treated with estrogen or vehicle for another 2 days. Afterward, cells were washed with PBS
and fixed in 0.4% paraformaldehyde overnight. Neutral lipids were stained using HCS
Lipid-TOX™ Green neutral lipid stains and nuclei were stained using 4′,6-diamidino-2-
phenylindole (DAPI) (Molecular Probes/Invitrogen, Carlsbad, CA) for 30 min at room
temperature. Cell images were acquired using ImageXpress Micro Widefield High Content
Screening System and analyzed using MetaXpress software version 3.1.0.79 (Molecular
Devices, Inc., Sunnyvale, CA).
Cell proliferation assays
Cell proliferation assays were performed using 3-(4,5-dimethyl-thiazol-2-yl)-5-(3-
carboxymethoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assays in tandem with
cell counting. After the indicated number of days, MTS assays were performed using the
CellTiter 96 kit (Promega, Madison, WI). Cell numbers were determined using the Countess
Automated Cell Counter (Invitrogen, Carlsbad, CA).
Results
SLC22A5 is expressed in breast cancer
In our previous transcriptional profiling study, we observed that SLC22A5 is an estrogen-
induced gene in breast cancer cells [18]. However, no information is available regarding
SLC22A5 in breast cancer. To gain a better understanding of the regulation and function of
the SLC22A5 gene in breast cancer, we first examined SLC22A5 expression in a panel of
breast cancer cell lines. As shown in Fig. 1a, SLC22A5 is expressed in all the breast cancer
cell lines examined. Of special interest, SLC22A5 expression is significantly overexpressed
in ER-positive cell lines compared with ER-negative cell lines (P < 0.001; Fig. 1b, left
panel). Similar results were obtained upon analysis of the cDNA microarray dataset of
breast cancer cell lines [48] (P < 0.001; Fig. 1b, right panel). Examination of SLC22A5
expression in breast tumor tissue specimens through clinical microarray dataset [33–47]
analysis further supported SLC22A5 expression being significantly over-expressed in ER-
positive tumor tissue specimens compared with ER-negative tumor tissue specimens. In fact,
this held true in all 15 independent datasets studied, including more than 2,000 patients (Fig.
1c). We also found that SLC22A5 expression correlates significantly with ER expression in
breast tumor tissue specimens using data from these clinical microarray datasets (P <
0.0001, Fig. 1d).
SLC22A5 expression is upregulated by estrogen
Due to the correlative relationship between SLC22A5 and ER mRNA levels, our next step
was to examine the effect of estrogen treatment on SLC22A5 expression in different cell
lines. As shown in Fig. 2a, E2 induced SLC22A5 expression in ER-positive cell lines, but
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had no effect on its expression in ER-negative cell lines. To investigate the molecular
mechanism by which estrogen induces SLC22A5 gene expression, we chose MCF-7 as a
model system for further studies, as this cell line displayed the highest E2-regulated
induction of SLC22A5 expression. We first examined SLC22A5 expression in response to
estrogen at different time points. As shown in Fig. 2b, E2 induces SLC22A5 mRNA
expression very rapidly. This induction could, in fact, be detected within 0.5 h, peaking at 2
h, and remaining elevated thereafter (Fig. 2b). In order to determine whether E2-induced
SLC22A5 expression is through a primary transcriptional regulatory mechanism, as
suggested by the expression-over-time analysis, we tested the effect of E2 on SLC22A5
expression in MCF-7 cells pretreated individually with inhibitors of RNA synthesis, ActD,
and protein synthesis, CHX, versus that observed with the vehicle, DMSO. As shown in Fig.
2c, ActD, but not CHX, was able to block E2 induction of SLC22A5 expression, indicating
that estrogen-regulated induction of SLC22A5 expression requires RNA, as opposed to
protein, synthesis. Next, we investigated whether ER is required for estrogen induction of
SLC22A5 expression. ICI 182.780 (ICI), a pure ER antagonist, completely blocked E2-
induced expression of SLC22A5 (Fig. 2d). Moreover, siRNA to ER similarly abolished E2
induction of SLC22A5 expression (Fig. 2e). These results indicate that E2 induction of
SLC22A5 expression is through a primary transcriptional regulatory mechanism, and
further, that this regulation is absolutely dependent on ER.
The SLC22A5 proximal promoter is not responsive to estrogen
Since SLC22A5 is an ER/E2-dependent gene, we wished to further define the physical
nature of the interaction and chose to investigate whether the SLC22A5 proximal promoter
was responsible for the gene’s estrogen inducibility. As estrogen may regulate gene
expression by binding to an ERE or by tethering other transcription factors at gene promoter
regions, this seemed a logical location for ER/E2 interaction with SLC22A5. We tested three
SLC22A5 promoter luciferase reporter plasmids with different promoter fragments lengths
and found that none of the constructs were responsive to estrogen treatment (Fig. 3a). The
−527 to +39 bp fragment retains strong basal activity and is regarded as the core promoter.
This portion of the proximal promoter was used for the following experiments.
A downstream enhancer confers SLC22A5 estrogen responsiveness
Since the SLC22A5 proximal promoter was unresponsive to estrogen, we examined
SLC22A5 gene structure in a global genomic context and found a potential ER binding
region located approximately 9 kb downstream of the transcriptional start site (Fig. 3b). This
region has been identified in two independent genome-wide studies and may therefore
contain a functional ER binding site [16, 17]. The potential ER binding region (1,063 bp)
encompasses a portion of introns 1 and 2, as well as exon 2 in its entirety. We cloned this
DNA fragment and inserted it downstream of the SLC22A5 promoter–luciferase gene
cassette in a manner resembling native SLC22A5 genomic structure. This SLC22A5
promoter–luciferase gene-intronic fragment construct is dramatically induced by estrogen,
indicating that the ER binding region included, the 1,063 bp fragment, functions as an
enhancer, thereby contributing to the estrogen responsiveness of SLC22A5 (Fig. 3c).
The enhancer contains an ERE and multiple transcription factor binding sites
Since this intronic enhancer enables estrogen-regulated induction of the SLC22A5 promoter,
we next sought to determine which cis-acting elements and their cognate trans-acting factors
are required for estrogen induction. We analyzed this intronic enhancer region and identified
many potential transcription factor binding sites, of which those previously shown to be
related with the ER signaling pathway are presented in Fig. 3d. Interestingly, four potential
transcription factor binding sites are juxtapositioned in the middle of this intronic enhancer:
sequentially, a hERE, an activator protein-1 (AP-1) site, a full ERE, and CRE. These
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elements are located within a small stretch of DNA only 113 bp in size. We cloned this 113
bp fragment containing the four elements in addition to the 3 bp flanking protective
sequences on either side of the string of transcription factor binding sites and inserted the
full 119 bp DNA fragment into the SLC22A5 promoter–luciferase construct. This small
fragment is highly responsive to estrogen, retaining at least 75% of the estrogen inducibility
of the 1,063 bp full-length enhancer (data not shown). Therefore, the estrogen-responsive
region must be located within this 119 bp strand of DNA.
Since an ERE-like sequence, GGTCA-CTG-TGACT, is located in this enhancer, we
hypothesized that it would act as a functional ERE. Therefore, we generated plasmids with
deletions or mutations within this ERE-like element. Indeed, deletion of the entire 13 bp
ERE-like sequence, as well as a mutation of 2 bp in either the left or the right half of the
ERE site abolished estrogen responsiveness (Fig. 3e). These results clearly identify this 13
bp ERE-like sequence (GGTCA-CTG-TGACT) as a new intronically located ERE, which is
only 1 bp different from the classical vitellogenin ERE (vit-ERE) consensus sequence
(GGTCA-NNN-TGACC) [49].
To determine whether other specific elements within the enhancer region are also required
for estrogen responsiveness, we generated several additional constructs carrying a mutation
within the hERE, AP-1, or CRE sites and tested whether any affected estrogen
responsiveness. Manipulation of either the hERE (TGACC) or the potential CRE site
(TGACATCA) significantly decreased estrogen-induced luciferase activity by about 50%,
whereas mutation of the potential AP-1 site (TGATTCA) had little effect on estrogen-
induced luciferase activity (Fig. 3e). These results suggest that the cAMP/CRE binding
(CREB) pathway rather than AP-1 pathway may be involved in estrogen regulation of
SLC22A5 expression. To test this hypothesis, we used a dual approach: (1) stimulating the
cAMP pathway or AP-1 pathway using the associated activating chemicals (FSK, an
activator of adenylyl cyclase, or TPA, an activator of AP-1, respectively) (see Fig. 4a), and
(2) abrogating the pathways using siRNAs against CREB1/ATF2 or AP-1 proteins (see Fig.
4b). Intriguingly, none of these approaches affected basal or estrogen-stimulated SLC22A5
gene expression (Fig. 4a, b).
An NR4A2/Nurr1 site overlapping with the potential CRE site is critical for estrogen
induction of SLC22A5 expression
Based on the above findings that mutation of the potential CRE site significantly decreased
estrogen inducibility while activation or abrogation of cAMP pathway did not affect either
the endogenous or estrogen-induced SLC22A5 expression, we hypothesized that this
potential CRE site is not functional but that mutation of the site may simultaneously affect
another cis-acting element. If this is the case, then binding of a trans-acting factor
contributing to estrogen inducibility specific for the alternate cis-acting element could be
affected by the mutation. We analyzed this enhancer region and found a potential NR4A2/
Nurr1 binding site (ATGTCA, minus strand) that overlaps with the potential CRE site
(TGACATCA, plus strand).
NR4A2 gene is a member of the steroid–thyroid hormone–retinoid receptor superfamily [50,
51]. The encoded protein, Nurr1, is an orphan nuclear receptor that acts as a transcription
factor [52]. We used a dual method approach to test our hypothesis of NR4A2/Nurr1
involvement in the estrogen induction of SLC22A5 expression. First, we abrogated the
NR4A2/Nurr1 pathway using NR4A2 siRNAs. siRNA knockdown of NR4A2 partially
blocked E2-induced SLC22A5 expression without affecting the basal level of SLC22A5
expression (Fig. 4b). Second, we overexpressed the Nurr1 transcription factor by
transfection of the cytomegalovirus-nuclear receptor related 1 (CMV-Nurr1) plasmid.
Overexpression of Nurr1 not only stimulated SLC22A5 expression, but also cooperated with
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E2 to induce SLC22A5 expression to a higher extent (Fig. 4c). These results demonstrate
that NR4A2/Nurr1 is involved in estrogen induction of SLC22A5 gene expression.
ER and Nurr1 proteins are recruited to the intronic enhancer
In order to validate the recruitment of transcription factors to the SLC22A5 intronic
enhancer and proximal promoter elements, we performed ChIP experiments.
Immunoprecipitated DNA was analyzed by q-PCR using primers for both the SLC22A5
intronic enhancer and proximal promoter (Fig. 5a). Primers for the pS2 gene promoter and
primers for intron 1 of the SLC22A5 gene were used as positive or negative controls,
respectively (data for positive control not shown) (Fig. 5a). Upon treatment with E2, both
ER and Nurr1 were recruited to the intronic enhancer within intron 2 as opposed to the
proximal promoter region (Fig. 5b). By contrast, neither CREB1 nor ATF2 were recruited to
either the SLC22A5 intronic enhancer or the proximal promoter regions. In addition to the
observed Nurr1 localization, integrator proteins CREB binding protein (CBP) and E1A
binding protein p300 (p300) were also recruited to the intronic enhancer, as well as to the
promoter. RNA polymerase II (Pol II), on the other hand, was recruited to the proximal
promoter and introns 1 and 2 upon E2 treatment.
The physiological relevance of SLC22A5 expression in breast cancer
SLC22A5 gene encodes a polyspecific organic cation transporter with sodium-dependent
high affinity to carnitine, which is an essential nutrient involved in fatty acid transport into
mitochondria and oxidation to produce energy. To investigate whether SLC22A5 is involved
in carnitine transportation and lipid metabolism in breast cancer, we performed carnitine
transport assays examining carnitine intake in breast cancer cells in response to estrogen
treatment. As shown in Fig. 6a, E2 treatment resulted in increased carnitine intake into
MCF-7 breast cancer cells. We also tested the effect of downregulation of SLC22A5
expression on carnitine intake. In this case, carnitine intake was inhibited by pretreatment
with siRNA against SLC22A5 (Fig. 6b). Further examination of carnitine intake in another
cell line (T47D) revealed similar results (data not shown). Collectively, these results
demonstrate that SLC22A5 functions as a carnitine transporter in breast cancer cells.
Since carnitine is a critical regulator of fatty acid transport and lipid metabolism, we
investigated the possible effects of SLC22A5 on lipid content. As shown in Fig. 7,
SLC22A5 knockdown resulted in increased lipid droplet accumulation in vehicle-treated
cells. Estrogen treatment was able to prevent the accumulation of lipid when SLC22A5 was
knocked down. This result is consistent with our studies showing that estrogen upregulates
SLC22A5 expression and rescued the effect of SLC22A5 knockdown (Fig. 7).
Since previous studies have shown that increased cellular lipid content is associated with
both a less malignant state and a reduction in cell growth rate [53], we assessed the
proliferation of breast cancer cells after knockdown of SLC22A5 expression. siRNA against
SLC22A5 significantly inhibited growth of three ER-positive and three ER-negative breast
cancer cell lines, indicating the functional importance of SLC22A5 in cell proliferation at a
fundamental level (Fig. 8). Confirmation of these results was achieved through MTS assay,
the results of which were in accordance with our initial findings (data not shown). Taken
together, these results demonstrate that SLC22A5 is a critical gene for carnitine intake, lipid
metabolism, and breast cancer cell proliferation.
Discussion
Estrogen and its receptors regulate many genes implicated in breast cancer. Indeed, the ER/
E2 signaling pathways play an important role in the pathogenesis of breast cancer. Although
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transcriptional profiling studies have shown that thousands of genes are regulated by ER/E2
in breast cancer, only a small number of genes have ER binding sites that have been
experimentally verified. Therefore, the molecular mechanisms of ER/E2 regulation of target
gene expression and biological function are not completely understood. Previous studies by
us and others have shown that ER/E2 regulate genes via different pathways, including the
classical genomic pathway [54] and transcription factor crosstalk (the tethering pathway)
[11, 12]. However, more complex mechanisms may also be involved in ER/E2 signaling in
breast cancer. Recent genome-wide studies have revealed that many ER binding sites are
located in distal regions rather than in proximal promoter regions [16, 17]. It has also been
demonstrated that the regulatory elements located within the intronic region are critical for
the regulation of many important genes in breast cancer, including ER [55], IGFBP-6 [56],
and ERBB2 [57].
In a previous genome-wide transcriptional profiling study, we identified SLC22A5 as a
novel estrogen-induced gene [18]. In the present study, we show that estrogen stimulates
SLC22A5 expression through an ER-dependent transcriptional regulatory mechanism via a
distal enhancer located in the second intron. We characterized a half ERE, a critical newly
identified full ERE, and an NR4A2/Nurr1 site, juxtapositioned within the intronic enhancer,
as important elements for estrogen induction of SLC22A5 expression. Finally, we found that
crosstalk between ER and Nurr1 is involved in the estrogen-regulated induction of
SLC22A5 expression.
Based on our results, we propose a novel molecular mechanism by which ER and Nurr1
cooperate to regulate SLC22A5 expression (Fig. 9). In this model, ER and Nurr1 are not
bound to the distal intronic enhancer region in the absence of estrogen, and SLC22A5 is
expressed at a low level. When estrogen is added to the cells, estrogen-liganded ER
translocates to the nucleus and the dimeric ER complex binds to the full ERE. This complex
is stabilized by the interaction of ER with Nurr1 binding to the NR4A2 site as well as
another ER binding to the half ERE. The ER–Nurr1 complex then functions as a
transactivator, interacting with RNA polymerase II bound to the SLC22A5 promoter region,
and ultimately upregulating SLC22A5 gene expression, and subsequently carnitine intake
and lipid metabolism, in breast cancer cells.
Previous studies have shown that SLC22A5 is highly expressed in the kidney and functions
primarily as a transporter of carnitine [19, 20], the level of which has been implicated in
lipid metabolism and energy production [21–23]. There are only a few studies of the
regulation of carnitine levels by sex hormones. For example, plasma carnitine concentration
decreases upon estrogen treatment in rats [58] and serum-free carnitine concentration is
inversely correlated with estrogen levels in women [59]. Estrogen has also been shown to
upregulate carnitine palmitoyltransferase I gene expression in rat skeletal muscle [60, 61].
These studies have demonstrated a potential role of estrogen in regulating carnitine
homeostasis, lipid metabolism, and cellular energy. However, no information is available to
date regarding the regulation and function of the SLC22A5 gene in breast cancer, or in any
other cancers. In this study, we demonstrate that estrogen treatment results in increased
carnitine intake into MCF-7 breast cancer cells. We also show that knockdown of SLC22A5
expression dramatically inhibits carnitine intake, increases lipid droplet accumulation, and
suppresses proliferation of breast cancer cells. The underlying mechanism in breast cancer
could be an interruption of carnitine transport due to SLC22A5 inhibition, thereby leading to
aberrant lipid metabolism, reduced cellular energy, and decreased cell proliferation. Since
estrogen is a mitogen, ER-positive cells require more carnitine intake for lipid metabolism
and growth, which may be the evolutionary reason why an ERE is present in the SLC22A5
regulatory region.
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In summary, the study presented here demonstrates that SLC22A5 expression is regulated
by estrogen via a novel intronic ERE and indicates that SLC22A5 is required for carnitine
intake, lipid metabolism, and proliferation of breast cancer cells. This study provides novel
insights into the underlying molecular mechanism by which estrogen regulates metabolism
and proliferation, and also raises the potential for specifically targeting SLC22A5 for the
treatment of breast cancer in the future.
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SLC22A5 expression in breast cancer. a SLC22A5 expression in breast cancer cell lines as
determined by qRT-PCR. b SLC22A5 expression in ER-positive and ER-negative cell lines.
Left panel qRT-PCR data of this study; right panel cDNA microarray dataset [48]. c
SLC22A5 expression in breast tumor tissue specimens from 15 studies including a total of
more than 2,000 patients. Studies 1–15 are from the clinical microarray datasets [33–47]. d
The correlation between SLC22A5 and ER expression in breast tumor tissue specimens.
Shown is the correlation data from the largest dataset, comprised of 295 patients [42].
Analyses of other datasets also generated similar results (data not shown)
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SLC22A5 expression is regulated by estrogen. a E2 regulation of SLC22A5 expression in a
panel of breast cancer cell lines. Hormone-depleted cells were treated with vehicle/E2 for 6
h, followed by mRNA expression analysis by qRT-PCR. b Time course of E2 induction of
SLC22A5 expression in MCF-7 cells. c Effects of ActD and CHX on E2 induction of
SLC22A5 expression. Hormone-depleted MCF-7 cells were treated with ActD (1 μg/ml) or
CHX (10 μg/ml) for 1 h before the addition of vehicle/E2. RNA was harvested 2 h after
treatment with vehicle/E2. d Effect of ICI 182.780 (ICI) on E2 induction of SLC22A5
expression. Hormone-depleted MCF-7 cells were treated with ICI (1 μmol/l) for 1 h before
the addition of vehicle/E2. RNA was harvested 2 h after treatment with vehicle/E2. e Effects
of siRNA against ER induction of SLC22A5 expression. Hormone-depleted MCF-7 cells
were transfected with siRNA against luciferase (Luc) or estrogen receptor (ER) for 36 h
before the addition of vehicle/E2. RNA was harvested 2 h after treatment with vehicle/E2.
Inset verification of ER knockdown by Western blot
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Luciferase assay of SLC22A5 enhancer/promoter luciferase constructs. a Effect of E2 on the
reporter activity of different lengths of SLC22A5 promoter luciferase constructs. Hormone-
depleted MCF-7 cells were transfected with different lengths of SLC22A5 promoter
luciferase plasmids for 16 h. Cells were then treated with vehicle/E2 for 6 h and lysed for
luciferase analysis. b Schematic representation of SLC22A5 gene structure in the genomic
context, showing the ER binding site (chr5:131741886-131742949, +8544 to +9607 from
the transcriptional start site), visualized using the UCSC genome browser
(http://genome.ucsc.edu). c Effect of E2 on the reporter activity of the SLC22A5 promoter
luciferase construct with or without the intronic +9 kb enhancer. Luciferase analysis was
performed as described above. d Potential transcription factor binding sites within the
intronic +9 kb enhancer, showing the predicted half ERE, AP-1 site, full ERE, and CRE/
NR4A2 site. e Effect of E2 on the reporter activity of SLC22A5 promoter-enhancer
luciferase constructs, each carrying a deletion or mutation within one of the predicted
binding sites. Luciferase analysis was performed as described before
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Effects of the AP-1, cAMP, and Nurr1 pathways on SLC22A5 expression. a Effect of small
molecule chemicals for AP-1 and cAMP pathways on estrogen-induced SLC22A5
expression in MCF-7 cells. TPA or FSK was added with vehicle/E2 for 2 h. RNA was
harvested and analyzed by qRT-PCR. b siRNA knockdown of ER, AP-1, CREB1, ATF2, or
Nurr1 on estrogen-induced SLC22A5 expression. Hormone-depleted MCF-7 cells were
transfected with siRNA against each gene, as indicated, for 36 h. The cells were then treated
with vehicle/E2 for 2 h. The data for siLuc transfected and vehicle-treated samples were
arbitrarily set as 1. The efficiency of the siRNAs has been validated to suppress the
expression of target genes as shown in the Western blot. c Effect of Nurr1 overexpression on
estrogen-induced SLC22A5 expression. Hormone-depleted MCF-7 cells were transfected
with vector (vec) or CMV-Nurr1 plasmid for 36 h and then treated with vehicle/E2 for 2 h.
RNA was harvested and analyzed by qRT-PCR. Inset verification of Nurr1 expression by
Western blot
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ChIP assay of the recruitment of transcription factors to the SLC22A5 gene locus. a
Schematic representation of the primers used to amplify the SLC22A5 promoter, intron 1, or
intronic enhancer (within intron 2) regions. b Recruitment of ER, Nurr1, CREB1, ATF2,
p300, CBP, and Pol II to the SLC22A5 promoter, intron 1, or intronic enhancer (within
intron 2) regions. Data were presented as the relative amount of immunoprecipitated DNA
normalized to input as measured by q-PCR assay. The data for vehicle-treated samples were
arbitrarily set as 1
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Carnitine intake in MCF-7 breast cancer cells. a Effect of E2 on carnitine intake. Right panel
verification of upregulation of SLC22A5 expression in response to E2. b Effect of siRNA
against SLC22A5 on carnitine intake. Right panel verification of knockdown of SLC22A5
expression by its siRNA
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Lipid droplet accumulation in MCF-7 breast cancer cells. a Fluorescent images of cells
stained with HCS LipidTOX (green fluorescence) and DAPI (blue fluorescence). b
Quantification of lipid content. c SLC22A5 expression in cells transfected with siRNA
against Luc/SLC22A5 and treated with vehicle/E2
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Cell proliferation as determined using the Countess Automated Cell Counter. a ER-positive
cell lines, b ER-negative cell lines
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Schematic representation of the molecular mechanism by which estrogen regulates
SLC22A5 gene expression
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